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ABSTRACT
The prevalence of presbyopia continues to
increase every year. The therapeutic approaches
to presbyopia cover the spectrum of non-surgi-
cal to surgical techniques. With recent advances
in biocompatible materials, corneal inlays make
a strong case for their place within the treat-
ment spectrum. This article takes a closer look
at three of the current corneal inlay models:
KAMRA, Raindrop, and Presbia Flexivue Micro-
lens. Each design approach and mode of action
is described with data from key clinical trials.
Furthermore, the ability to choose the most
suitable corneal inlay is presented by comparing
each model and identifying their similarities
and differences. The article then concludes by
touching on the future of corneal inlays, look-
ing at associated conditions and complications
and how to manage them, as well as an expert’s
personal point of view of enhanced ideas for
continuing the growth and success of corneal
inlays in the market.
Keywords: Corneal inlay; KAMRA; Presbia
Microvue; Presbyopia; Raindrop
INTRODUCTION
Presbyopia is an age-related progressive decline
in the crystalline lens’ ability to accommodate,
resulting in the inability to focus on near
objects [1]. The impact presbyopia has on the
quality of life on our aging global population
has placed presbyopia treatment in the fore-
front of significant research [2]. With a pro-
jected prevalence of 2.1 billion people affected
worldwide by 2020, combined with the docu-
mented negative health-related impacts, the
treatment spectrum has been evolving rapidly
[3–5].
The symptoms of presbyopia begin around
the age of 40 years old [6]. One of the difficulties
associated with presbyopia is that its patho-
physiology remains poorly understood. The
Helmholtz theory of accommodation is the
most widely accepted proposed mechanism,
which is based on the assumption that the
change in the lens shape is due to the change in
the ciliary muscle diameter. During accommo-
dation, the ciliary muscle contracts, relaxing
the tension on the zonular fibers, thus resulting
in a reduced overall lens diameter. This relaxed
zonular state allows the lens to obtain a more
spherical shape, which leads to an overall
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increase in refractive power. The opposite
occurs in cycloplegia: when the ciliary muscle is
relaxed, the tension on zonular fibers is
increased causing the lens to assume a more
flattened shape from the radial zonular tension.
This accounts for the diminished power of the
lens in cycloplegia [7]. There have been many
other postulated theories of presbyopia to
challenge Helmholtz’s theory, yet not one has
been universally accepted [8–10]. Dysfunctional
lens syndrome is a term that is gaining more
popularity in use for patient education and
satisfaction. It is a simple method to describe
the continuum of progression associated with
age related crystalline lens changes that can
help patients achieve a better grasp of their
presbyopia [11].
The history of surgical presbyopia treatment
has oscillated with numerous promising ideas
that have fallen short of success. An early effort
included addition of human donor corneal tis-
sue to a patient’s host cornea to change the
refraction, a procedure called additive refractive
keratoplasty [12]. Then, in 1949, we were
introduced to Jose Barraquer’s first corneal inlay
prototype. Created for the treatment of high
myopia or aphakia, it was designed from poly-
methylmethacrylate or flint glass. These early
inlays showed initial signs of success in treating
the targeted refractive error. However, the
abhorrent rates of implant extrusion and cor-
neal necrosis from reactions to the material
quickly resulted in these inlays becoming out of
favor [12–14].
Two decades after Barraquer experimented
with his initial prototype, the concept was
revived with the discovery of more biocompat-
ible materials, like hydrogel [15]. These new
materials showed promise in that they were
transparent and permeable to fluids and nutri-
ents, which provided some assurance the cor-
neal tissue would tolerate them [16].
Unfortunately, the majority of these devices
were explanted because of the aggressive rates of
stromal thinning, melting, haze, inlay decen-
tration, and corneal opacification [17–20].
With the current non-invasive methods of
correcting presbyopia (i.e., bifocal or multifocal
progressive spectacle lenses) falling out of favor
because of the increased desire for spectacle
independence, we look toward the new gener-
ation of novel concepts of presbyopia treatment
[13]. Presbyopia’s therapeutic options have
been employed through corneal, lenticular, and
scleral surgical approaches in an effort to either
enhance depth of focus or attempt to restore
accommodation [21]. The purpose of this
review is to provide an overview of corneal
inlay-based procedures and devices currently in
use for the surgical treatment of presbyopia.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
CORNEAL INLAYS
Refractive surgery reached a milestone in inno-
vation with the development and introduction
of the new generation of corneal inlays for the
treatment of presbyopia [13]. Using newer
materials with enhanced biocompatibility
alongside advances in technology (i.e., the
Femtosecond Laser) has raised the ceiling of
successful outcomes for our patients [22, 23].
Additional features of the inlays that have
amplified their success include their thin
design, small diameters, high nutrient and fluid
permeability, and the capacity to be implanted
relatively deep within the stromal tissue. Previ-
ous large and impermeable inlays disrupted the
cornea’s natural state by hindering natural
metabolic functions. Depth of placement varies
for each inlay design, given the different mate-
rials and mechanisms each provides. Inlays
designed to utilize a small aperture or a different
index of refraction are usually implanted deeper
to avoid unintended changes in surface curva-
ture, whereas inlays designed to deliberately
modify the surface curvature are placed more
superficially. It should be noted that there are
inherent risks with surgical approaches, and one
should consider balancing the positives and
negatives between comfort and safety when
discussing the surgical treatment of presbyopia
with corneal inlays.
Another advantage of these corneal inlays is
that they are additive and do not actually
remove any tissue, which preserves the capacity
Ophthalmol Ther
for reversal/removal or future options of any
other type of presbyopia correction [4]. This is
true only when there are no complications of
corneal scarring, opacification, stromal thin-
ning, or melting, which may occur in the
aftermath of corneal surgery. After designated
implantation in the non-dominant eye, inlay
procedures can be combined with other refrac-
tive procedures. There tend to be fewer risks
associated with the corneal inlay surgery com-
pared to intraocular surgery, as these procedures
are all limited to the cornea. With monovision,
there is a one-to-one loss in distance vision for
every line gained in near vision. However, with
corneal inlays, the majority of patients lose only
1 or no lines of distance vision for about a 5–6
line improvement in near vision [24, 25].
The femtosecond laser offers consistency in
terms of creating a more dependable flap or
stromal pocket, which in turn provides
improved accuracy of implantation depth and
inlay centration [16, 26]. A major advantage of
the pocket technique, compared to the flap
technique, is the salvation of more peripheral
corneal nerves. This defends against the
diminished corneal sensation associated with
flap creation, which in turn allows for a reduced
incidence of dry eyes and a potential faster
visual recovery [26, 27]. Due to less tissue
alteration, a pocket procedure is theoretically
more biomechanically stable versus a lamellar
procedure. Pockets are also less likely cause
striae, which can be seen with lamellar flaps.
However, lamellar flaps do have scenarios where
they are more appealing than a pocket creation
such as when an inlay is placed in combination
with an excimer laser procedure to attain ame-
tropia. The flap procedure is preferred as it
allows for easy access in case the inlay is
decentered or requires explantation [28].
Another option includes the creation of a stro-
mal pocket roughly 100–120 microns deeper to
a previous or sequential LASIK flap if refractive
surgery is combined with the inlay at that time.
Currently, there are three available styles of
corneal inlays: the Flexivue MicrolensTM (Pres-
bia Coo¨peratief U.A., Irvine, CA, USA); the
Raindrop Near Vision Inlay (ReVision Optics,
Lake Forest, CA, USA); the KAMRATM inlay
(AcuFocus Inc., Irvine, CA, USA) (Table 1).
PRESBIA FLEXIVUE MICROLENS
The Flexivue Microlens is a refractive optic
corneal inlay that functions by altering the
Table 1 Comparison of the three corneal inlays
Diameter Thickness Flap/pocket
placement
Mechanism of action Centration Material
Raindrop 2 mm 32 lm 120–200 lm Increase central radius of
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corneal index of refraction to improve near
vision performance, by the means of a bifocal
optic, which separates distance and near focal
points. The basic principle is corneal multifo-
cality, providing distance vision through a
plano central zone surrounded by 1 or more
rings of varying additional power for interme-
diate and near vision [13, 26]. The Flexivue
Microlens is a 3-mm-diameter, transparent
hydrogel-based implant made from a hydro-
philic copolymer of hydroxyethyl methacrylate
and methyl methacrylate, and it contains an
ultraviolet blocker. Depending on the add
power, the thickness of the inlay varies from 15
to 20 lm [13, 16, 28, 29]. The central zone is
optically neutral with a refractive peripheral
zone that provides add powers between ?1.25
and ?3.5 D, in ?0.25 D increments. The central
portion of the inlay has a 0.15-mm opening
that facilitates fluid, nutrient, and oxygen
transfer across the cornea [27]. The inlay mate-
rial has a refractive power of 1.4583 and light at
wavelengths above 410 nm have a transmission
of 95% [13, 27]. The inlay is placed in a fem-
tosecond created corneal pocket that is
280–300 lm deep [28]. Centration of the Flex-
ivue Microlens is based on placement over the
first purkinje image. Given its relatively deep
placement within the cornea, usually no cor-
neal topography changes are seen.
To date, Presbia has implanted 1000? inlays,
including 421 implants in their US Investiga-
tional Device Exemption study. The Flexivue
Microlens received its CE Mark in 2009. It is
currently approved in 42 countries. Currently in
the US, Presbia is in a Phase III trial for FDA
approval and has completed enrollment.
In one study, Pallikaris et al. reported results
on 43 patients with an average preoperative
uncorrected distance visual acuity (UDVA) of
20/20 and an average uncorrected near visual
acuity (UNVA) of 20/50. After 1 week, every
patient had an increase in UNVA, and after
1 year 93% of patients were reported to have an
UNVA of J2 or better [29]. Limnopoulou et al.
reported the refractive outcomes of 47 presby-
opic emmetropic patients who received the
Flexivue Microlens over a 12-month period [27].
Their 1-year postoperative findings showed 75%
of their patient’s UNVA was 20/32 or better. The
UDVA showed a statistically significant decrease
of 3 lines from preoperative (20/20) to postop-
erative (20/50) values. However, binocular
UDVA did not show a statistically significant
decrease. Measurements of best corrected dis-
tance visual acuity (CDVA) in the operative eye
showed 37% lost 1 line, but no one lost 2 lines
or more. There were no intra- or postoperative
complications in this study, no inlay explanta-
tion or replacement, and no corneal tissue
alterations on confocal microscopy. The study
found a statistically significant increase in
higher order aberrations and a statistically sig-
nificant decrease in contrast sensitivity in both
mesopic and photopic settings. Even though
12.5% of patients complained of glare and halos
at the end of the 12-month period, the overall
level of satisfaction and independence from
spectacles was high [27].
RAINDROP NEAR VISION INLAY
The Raindrop falls into the category of
space-occupying corneal reshaping inlays that
function to create a hyperprolate cornea. The
Raindrop inlay is a clear lenticule made from
hydrogel, which allows fluid, nutrients, and
oxygen permeability, ensuring a stable corneal
environment. The lenticular diameter is 2 mm
with a central thickness of 32 lm, decreasing to
about 10 lm in the periphery. The refractive
index and water content of the Raindrop are
approximately equal to the human cornea. The
Raindrop itself has no actual refractive power. It
is placed and centered over a light constricted
pupil. When inserted under a LASIK flap or
intracorneal pocket at a relatively shallow depth
between 120 and 200 lm, the anterior central
radius of the curvature of the cornea overlying
the inlay is increased. The induced hyperprolate
shape with epithelial remodeling creates a
multifocal cornea, improving both near and
intermediate vision [30, 31]. The changes of the
induced hyperprolate shape are appreciated on
corneal topography scans, which demonstrate a
profocal cornea. The pseudoaccommodative
capacity of the Raindrop is enhanced with a
constricted pupil, as the incoming light rays
pass through the heightened cornea. Distance
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vision is theoretically negligibly affected, espe-
cially with a dilated pupil, since the paracentral
light rays are unaltered around the implant [28].
To date there have been about 4000–6000
Raindrop implanted worldwide. Raindrop has
been approved for concurrent LASIK, pseu-
dophakes, and emmetropes in the EU (2011),
Singapore and Hong Kong (2011), South Korea
(2014), Australia and New Zealand (2014). In
the USA, Raindrop gained FDA approval in
2016.
Barragan Garza et al. published the first
peer-reviewed paper about the Raindrop. Their
prospective study followed 20 emmetropic
patients with presbyopia for 12 months. Results
at the end of the year showed an average UNVA
20/25 (0.1 logMAR) or better with the average
UDVA 20/32 (0.2 logMAR) or better in the oper-
ated eye [30]. Besides one patient who was dis-
satisfied with the inlay and had it removed
because of an UDVA of 20/50 (0.4 logMAR), the
study overall showed high patient satisfaction
with minimal effects on UDVA. Postoperative
average photopic contrast sensitivity levels were
similar to the preoperative values at both the 6-
and 12-month visits and were considered to be
within normal limits of a phakic eye [30, 32, 33].
At the end of the 12 months, 100% of patients
stated theywere very satisfiedwith their distance
vision and the overall visual outcome, and 95%
stated they were satisfied or very satisfied with
the intermediate and near vision outcomes,
while 84% reported that they never or rarely
relied on glasses. Of note, the patient who had
the Raindrop removed, returned to an UDVA of
20/20 (0.0 logMAR) by 1 month. The Raindrop
confers the same adverse risks as the other cor-
neal inlays, and besides the explantation, one
patient required a repositioning [30].
Later Garza et al., enrolled 30 eyes to evalu-
ate the efficacy of concurrently implanting the
Raindrop with LASIK surgery in myopic pres-
byopes and then comparing these with results
of the same treatment in emmetropic and
hyperopic eyes [34]. At 6 months postopera-
tively, 93% of patients had binocular UNVA,
UIVA, and UDVA of 20/25 or better [34]. This
quickly established this procedure as safe and
effective for treating presbyopic patients with
myopia.
In one study, Chayet et al. looked at simul-
taneous refractive laser vision correction and
Raindrop implantation. This prospective study
enrolled 16 hyperopic presbyopic patients [35].
Results suggested a new indication for this
implant. By the 1-week postoperative visit,
100% of patients achieved an UNVA of 20/32 or
better. By the end of 1 year, mean monocular
and binocular UNVA was 20/27 or better.
Uncorrected intermediate and distance visual
acuities were also satisfactory averaging 20/26
and 20/31, respectively [35]. There was one
patient who suffered from recurrent haze and
had the Raindrop explanted after 9 months.
Overall 87% of patients stated being satisfied or
very satisfied with their near, distance, and
overall vision. Haloes and glares were studied, as
they can be an issue for post-LASIK patients,
and were found to be negligible in this study
[35, 36]. Contrast sensitivity was not monitored
in this study.
In another similar study of simultaneous
LASIK combined with the hydrogel implant,
greater than 80% of the enrolled 25 hyperopic
presbyopes were found to have an UNVA of J1
or better. Uncorrected intermediate visual acu-
ity was averaged at 20/25, which is an overall
improvement of roughly 5 lines per patient.
One patient had a loss of 1 line of UDVA, but
overall UDVA averaged a 2-line improvement
[37].
One series looking at 18 hyperopic eyes
receiving the raindrop demonstrated an average
improvement in UNVA of C5 lines 1 month
postoperatively. Fourteen of the 18 (78%)
implanted eyes were able to achieve an UNVA
of 20/20 or better. There was an average
improvement of 4 lines in UIVA, and the mean
UDVA was 20/25 [38].
KAMRA SMALL APERTURE INLAY
The KAMRA inlay functions to increase depth of
focus with the use of the pinhole principle. The
inlay has a total diameter of 3.8 mm with a
central hole, or aperture, measuring 1.6 mm
[39]. The small aperture effectively blocks
bending rays of light, minimizing refraction,
and thus increases depth of field. This improved
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near vision is achieved without a significant
change to distance vision. The opaque implant
is made from an enhanced biomaterial,
polyvinylidene fluoride, which only allows
6.7% of light transmission [13]. The KAMRA is
only 6 lm thick with 8400 laser-etched
microperforated holes, 5 to 11 lm in diameter,
arranged in a pseudorandom pattern permitting
adequate nutrient flow. The metabolic home-
ostasis attained with this implant avoids com-
plications such as epithelial decompensation or
corneal thinning. Centration of the KAMRA
inlay is based on placement over the first
purkinje image. Given its relatively deep place-
ment within the cornea, usually no corneal
topography changes are seen.
In 2005, the KAMRA inlay received the
Conformite´ Europe´enne (CE) mark, which
approved its use in the European Union. Out-
side of the USA, the KAMRA inlay is approved in
over 50 countries, and estimates of over 20,000
worldwide implants have been recorded [4, 40].
With such a presence in the field, the KAMRA
inlay is the most studied corneal inlay available.
Like the other presbyopia-correcting inlays, the
KAMRA inlay is implanted in the non-domi-
nant eye in the line of sight. The depth of the
lamellar pocket is usually around 250 lm,
unless previous LASIK has been performed, in
which case a dual interface technique is
employed, with the inlay placed about 100 to
110 lm beneath the previous LASIK flap [28].
The KAMRA inlay improves near and inter-
mediate visual acuity without a detrimental
change in distance vision. The small aperture
does not produce any splitting of light between
the near, intermediate, and distance focal
points, allowing a continuous range of vision.
Stereoacuity is not significantly decreased either
because the KAMRA inlay allows sufficient
binocular input and does not blend vision
[25, 41]. The KAMRA inlay has been used
effectively in natural emmetropic patients,
post-LASIK emmetropic patients, with LASIK
correction as a simultaneous or two-step
sequential procedure, and pseudophakic
patients with a monofocal or phakic intraocular
lens [5, 29, 35, 36, 39, 42–46]. The best refrac-
tive outcomes are seen in non-dominant eyes
with a small amount of residual myopia,
-0.75D to -1.00D, with less than 0.75D of
astigmatism and plano refraction in the domi-
nant eye [5, 42, 43, 47].
Safety of the inlay has been well documented
in human and animal studies. Standard risks of
complications during refractive surgery are
conferred to the KAMRA inlay. The healing
response is a major risk of an adverse outcome
with possible stromal thickening over the inlay
causing a hyperopic shift from the flattened
overlying epithelium [28]. Other adverse events
have been reported such as corneal haze,
epithelial iron deposition, and infectious ker-
atitis [48, 49]. Unwanted outcomes can be
handled by removing the inlay. There may be
an associated shift in the patient’s refraction,
but the overall corrected visual acuity was not
shown to change from preoperative measure-
ments [39].
Many studies looking at the outcomes of the
KAMRA inlay have been encouraging. Tomita
and colleagues published findings of 223 post--
LASIK eyes that received this inlay. At 6 months
they showed a 4-line improvement in the mean
UNVA (J8 to J2). Even though the mean UDVA
showed a 1-line decrease after implantation,
from 20/16 to 20/20, there was a high level of
patient satisfaction in vision and spectacle
independence [42]. In a different study by the
same group, they looked at 360 eyes (180
patients) that received simultaneous LASIK and
the KAMRA inlay in the treatment of emme-
tropes, hyperopes, and myopes [36]. This study
helped assess the safety profile and efficacy
associated with these two procedures performed
simultaneously across all refractive errors. As
expected, the preoperative mean UDVA and
UNVA varied between each specific group but,
at the end of the study, no significant difference
was identified [36]. At 6 months, the emme-
tropic presbyopic patients had improvements of
6 lines in mean logMAR UNVA and 1 line in
mean logMAR UDVA. The hyperopic presby-
opes gained 7 and 3 lines, respectively. The
myopic group showed 2- and 10-line improve-
ments, respectively. Myopic patients who have
relatively good UNVA had the smallest average
gain of lines compared to their hyperopic and
emmetropic counterparts, who were the most
satisfied with spectacle independence and
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overall vision [36]. Overall, the safety and effi-
cacy of the simultaneous procedure were
proven.
A study by Seyeddain et al. on 32 eyes
reported 97% of patients reading at the J3 level
or better in the operative eye [44]. After 24
months, the mean binocular UNVA improved
from J6 preoperatively to J1. At 1 month, the
mean UIVA was 20/20 and remained that way at
the 24-month follow-up. The mean UDVA was
reported to be 20/16 binocularly and 20/20 in
the KAMRA implanted eye [44].
In the 4-year study by Yilmaz et al., reports
on 39 emmetropic presbyopic patients implan-
ted with the KAMRA inlay were collected.
Twenty-seven of the patients achieved emme-
tropia from prior hyperopic LASIK; the other 12
were natural emmetropes. At 1-year follow-up, a
large improvement was appreciated with the
mean UNVA results showing an increase from
J6 to J1?. The reports demonstrated an UNVA
of J3 or better in 100% of patients and J1 or
better in greater than 85% of patients [39]. With
mean binocular UNVA results of J1 or better
throughout the study, the reports were even
more encouraging. The concern for adverse
changes in UDVA were shown to be insignifi-
cant as the mean UDVA in eyes with the
KAMRA implanted remained 20/20 throughout
the 4 years. The UIVA was also satisfactory with
91% of patients seeing 20/32 or better [45]. This
study did have three inlays explanted during its
course, and even with small shifts from preop-
erative refraction measurements, there was no
decrease in CDVA [39, 45].
The longest follow-up study of 5 years pro-
vided by Dexl et al. showed 32 emmetropic
presbyopic patients with no statistically signifi-
cant difference in refractive error after inlay
placement [49]. The mean UNVA in the surgical
eye improved significantly after 1 year from J7/
J8 to J1, remained stable at J1 at the
36th month, and then decreased slightly to
J3 ± 2 lines at 60 months. The mean UIVA fol-
lowed a similar trend, improving from 20/32 to
20/25 at 12 months, remaining relatively
stable at 20/20 until 36 months, and decreasing
slightly to 20/32 ± 1.5 lines by 60 months. A
similar pattern was appreciated for both binoc-
ular UNVA and UIVA [49]. Mean UDVA in the
surgical eyes decreased from 20/16 to 20/20 at
12 months postoperatively, remained stable un-
til 36 months at 20/20, and then had an addi-
tional decrease to 20/25 at the 60-month
follow-up. There were a total of four adverse
events reported during the course of the study:
two decentered inlays required repositioning at
6 months, one patient had a hyperopic refrac-
tive shift with the KAMRA and had it explanted,
and the other patient developed epithelial
ingrowth shortly after implantation [49].
Besides a slight compromise in monocular and
binocular UDVA, the overall mean monocular
and binocular UNVA showed improvement.
Successful results in KAMRA inlay studies are
attributed to some key factors. The newer
commercially available model of the KAMRA
inlay (ACI7000PDT) was improved from the
previous model (ACI7000) by being manufac-
tured as a thinner product (6 lm instead of 10
lm). The change also decreased the average
annulus light transmission value from 7.5% to
6.7%. The number of laser-etched holes
increased from 1600 to 8400, but the diameter
of the holes decreased from 25 lm to *5 to 10
lm. These model changes have reduced the
overall visual disturbances patients experienced
with the older model. Other factors include the
method with which the KAMRA inlay is
implanted. The creation of an intracorneal
pocket with femtosecond laser technology sal-
vages the number of corneal nerves affected
compared to flap creation. This, in turn,
diminishes the risk of dry eye disease and thus
can improve outcomes. Use of the femtosecond
offers its own advantages over the microker-
atome, which include more predictable flap
thickness, quicker visual recovery, and overall
better UDVA results [50–52].
COMPARISON
Each inlay presents its own unique way of cor-
recting presbyopia. The Flexivue Microlens cre-
ates corneal multifocality by altering the
corneal index of refraction to improve near
vision performance. The 1.8-mm inlay has a
plano central zone with increasing add power
placed in the peripheral zones. It is made from
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hydroxyethyl methacrylate and methyl
methacrylate that contains an ultraviolet
blocker. The Microlens is usually implanted at a
depth between 280 and 300 lm. The hydrogel
Raindrop inlay has a 2 mm diameter with a
central thickness of 32 lm. This space-occupy-
ing inlay alters the eye’s refractive power by
increasing the cornea’s central radius of curva-
ture. Placed the most superficial of the three
inlays, it is usually placed at a depth of about
30% of the total thickness of the cornea, typi-
cally ranging between 150 and 180 lm. The
polyvinylidene fluoride KAMRA inlay is only 5
lm thick. With a total diameter of 3.8 mm, it
contains a 1.6-mm central aperture that func-
tions as a pinhole to increase depth of focus.
Also placed relatively deeper within the stroma,
the best outcomes come from a depth of 250 to
280 lm, unless combined with LASIK, in which
case it is placed at least 100 lm beneath the
LASIK flap.
Corneal inlays provide the refractive surgeon
a method to correct presbyopia without the
risks associated with intraocular surgery. They
are exceptionally attractive with their capacity
to provide a significant increase in near and
intermediate vision without compromising
distance vision. Based on the clinical evidence
presented, all three inlays demonstrate a mini-
mally invasive technique with tremendous
results. Additional advantages include their
capacity to be removed with no loss of
best-corrected visual acuity and the fact that
contrast sensitivity and stereoacuity are not
significantly diminished. Some experts believe
the Raindrop is best for patients with low levels
of hyperopia and virgin eyes that have not
undergone any prior refractive procedures. For
KAMRA, myopic patients with refractions from
-0.75 to -1.00 tend to do the best, and it can
be performed after or simultaneously with
LASIK.
CONCLUSION
The future of corneal inlays could parallel the
fast growth of the presbyopic population with
the desire of being spectacle independent. As
advancements in technology continue, a wider
variety of approaches is being seen with inlays.
Results are promising with combined placement
of an inlay with LASIK or with cataract surgery
[53]. Selection is dependent on the surgeon’s
belief concerning which treatment is best for
the patient, knowing that each inlay has its own
set of disadvantages. Unpredictable wound
healing and tear film dependence on final visual
outcomes are other facets challenging the
potential success of these products. Surgeons
need to be familiar with results and treatment of
this foreign body placed within the cornea, as
well as minimize the amount of steroids needed
to achieve this. Their future success depends
upon advancements in the biocompatibility of
the material used, decreasing the rate of com-
plications and having more predictable out-
comes. There is the possibility of a slight
decrease in UDVA monocularly, but binocularly
the patients are less likely to realize this
decrease and overall have an increased satisfac-
tion level with the outcomes.
Associated conditions and complications
need to be prevented and managed appropri-
ately. Surface disease management and
improvement are critical for optimal function.
Dry eye treatment has seen a recent surge of
newer medicines and technologies to help those
not finding relief with traditional conservative
methods. Studies have shown patients with
aqueous tear film deficiency finding symp-
tomatic improvement with new drops like Res-
tasis and Xidra. Minor non-invasive procedures
with machines such as LipiFlow address both
meibomian gland dysfunction and dry eye. Use
of diagnostic instruments, such as the AcuTar-
get HD, allow the ophthalmologist to ascertain
the surface health of the eye. Additionally, they
provide pre- and postoperative Purkinje images
that help guide and confirm placement of inlays
into their appropriate positions.
Some experts in the field have discussed
ideas of using anti-metabolite drugs in combi-
nation with inlays. Early results with surface
ablation techniques, most commonly associ-
ated with PRK, showed astonishing results of
corneal haze in as many as 10% of patients.
Antimetabolites, such as mitomycin C (MMC),
have been shown to be effective in preventing
haze after PRK, thus making it a safe and reliable
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procedure. The fear of haze induction after inlay
placement can be mitigated with MMC to help
prevent this complication from occurring. Fur-
ther advances in corneal inlays are being inno-
vated and studied with Presbyopic Allogenic
Refractive Lenticule (PEARL) techniques using a
SMILE lenticule as a corneal inlay [54].
There are three milestones in a patient’s life
from a refractive standpoint. The first is
achieving ocular maturity with some degree of
refractive error, the second is presbyopia during
the 5th decade of life, and the third is devel-
opment of cataracts. The first milestone is pre-
dictably corrected with an excimer laser, and
the third milestone is successfully corrected
with cataract surgery. An ideal solution for
presbyopia correction is yet to exist. The ulti-
mate challenge is the restoration of the crys-
talline lens with its natural accommodative
properties. In the meantime, inlays can have a
significant impact towards correcting the sec-
ond visual milestone. Continued work is nec-
essary to better understand the wound-healing
characteristics of all inlays. As the actual inlays
and method of insertion continue to improve,
we expect that the safety and efficacy of corneal
inlays will continue to improve and represent
an excellent method to correct presbyopia.
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